Latest revenue
$74.5M
as of 2025-12-31
Latest net income
$-62.6M
as of 2025-12-31
Net margin
-84.0%
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Medicinal Chemicals & Botanical Products (30 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think CGC is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $387.3M
- Enterprise value
- $241.0M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.79×
- Dividend yield
- 0.0%
- 52-wk high
- $2.38
- 52-wk low
- $0.84
- Beta
- —
- Shares out
- 377.9M
5-year trend
What this company does
Item 1. Business. Our Vision and Purpose Our vision is to unleash the power of cannabis to improve lives. As one of the first publicly traded, licensed cannabis producers in the world, our vision comes to life by harnessing the power of the plant, building a global cannabis company, and fostering a purpose-driven atmosphere for our employees. We are a collective of dynamic and engaged leaders, united by a passion for cannabis, focused on delighting our consumers and medical cannabis patients while creating value for our stakeholders and one another. Canopy Growth is a world-leading cannabis company which produces, distributes, and sells a diverse range of cannabis and cannabis-related…
AI summary unavailable — showing raw filing excerpt
Generated from CGC's filing dated 2025-05-30
Key risks
Item 1A. Risk Factors. An investment in us involves a number of risks. In addition to the other information contained in this Form 10-K and in other filings we make, investors should give careful consideration to the following risk factors. Any of the matters highlighted in these risk factors could adversely affect our business, results of operations, financial condition and growth prospects, causing an investor to lose all, or part of, their investment. The risks and uncertainties described below are those we currently believe to be material, but they are not the only ones we face. If any of the following risks, or any other risks and uncertainties that we have not yet identified or that…
AI summary unavailable — showing raw filing excerpt
Generated from CGC's filing dated 2025-05-30
Profitability
Gross margin
25.3%
7.7%Operating margin
-37.3%
43.9%Net margin
-190.5%
0.3%Return on equity
-122.8%
6.5%Return on assets
-65.2%
28.9%Leverage
Debt / equity
0.88×
44.7%Long-term debt / equity
0.62×
37.6%Debt / assets
46.9%
23.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | $74.5M | -0.3% | $-62.6M | +48.6% | -84.0% |
Q3 2025 2025-09-30 | $66.7M | +5.9% | $-1.6M | +98.7% | -2.5% |
Q2 2025 2025-06-30 | $72.1M | +8.9% | $-41.5M | +67.3% | -57.6% |
Q1 2025 2025-03-31 | $110.0M | -8.0% | $-220.8M | -139.1% | -200.7% |
Q4 2024 2024-12-31 | $74.8M | -4.8% | $-121.9M | +43.8% | -163.0% |
Q3 2024 2024-09-30 | $63.0M | -9.5% | $-128.3M | +58.6% | -203.7% |
Q2 2024 2024-06-30 | $66.2M | -13.2% | $-127.1M | -233.5% | -192.0% |
Q1 2024 2024-03-31 | $119.6M | — | $-92.3M | — | -77.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Medicinal Chemicals & Botanical Products · SIC 2833
Your notes
Keep private notes on CGC — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$50.0K
Insider selling
$299.1K
Net activity
−$249.1K
Distinct insiders
9
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CGC
Institutional value
$6.9M
Total shares held
7.3M
Distinct holders
157
-67 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC | 1.6M | $1.5M | -5.8M (-78.7%) | Trimmed |
| 2 | UBS Group AG | 939.4K | $891.5K | +605.0K (+180.9%) | Added |
| 3 | Sullivan Wood Capital Management LLC | 854.3K | $810.9K | +81.5K (+10.5%) | Added |
| 4 | SBI Securities Co., Ltd. | 616.9K | $585.5K | +71.6K (+13.1%) | Added |
| 5 | TD ASSET MANAGEMENT INC | 510.4K | $482.8K | +87.6K (+20.7%) | Added |
| 6 | MACKENZIE FINANCIAL CORP | 348.0K | $330.2K | +42.4K (+13.9%) | Added |
| 7 | Baader Bank Aktiengesellschaft | 348.0K | $290.9K | -28.9K (-7.7%) | Trimmed |
| 8 | AdvisorShares Investments LLC | 289.7K | $275.0K | -23.8K (-7.6%) | Trimmed |
| 9 | Foundations Investment Advisors, LLC | 220.0K | $208.8K | -205.0K (-48.2%) | Trimmed |
| 10 | SLT Holdings LLC | 220.0K | $208.8K | -205.0K (-48.2%) | Trimmed |
| 11 | LPL Financial LLC | 128.6K | $122.0K | +26.0K (+25.3%) | Added |
| 12 | TD Waterhouse Canada Inc. | 119.1K | $115.2K | +101.9K (+594.6%) | Added |
| 13 | Daiwa Securities Group Inc. | 120.8K | $114.7K | +106.9K (+769.1%) | Added |
| 14 | LAKE STREET PRIVATE WEALTH, LLC | 115.0K | $109.2K | +24.8K (+27.4%) | Added |
| 15 | Leonteq Securities AG | 75.1K | $98.7K | -67 (-0.1%) | Trimmed |
| 16 | Midwest Trust Co | 73.9K | $70.1K | -10.8K (-12.7%) | Trimmed |
| 17 | COMMONWEALTH EQUITY SERVICES, LLC | 70.5K | $66.9K | -3.2K (-4.4%) | Trimmed |
| 18 | Apollon Wealth Management, LLC | 48.5K | $46.1K | -1 (-0.0%) | Trimmed |
| 19 | WINTON GROUP Ltd | 47.6K | $45.2K | -7.7K (-13.9%) | Trimmed |
| 20 | Marex Group plc | 46.4K | $44.0K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CGC's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.